Skip to main content

Harvard Bioscience Shares Slide 5.73 Percent on Lackluster Q4 Results

NEW YORK, March 3 (GenomeWeb News) - Shares in Harvard Bioscience were down 5.73 percent,or $.30, at $4.94 in afternoon trade after the company late yesterday reported marginal fourth-quarter revenue gains and a $8.9-million loss.

 

As GenomeWeb News reported this morning, the company posted a 2.4-percent increase in revenues to $7.8 million.

The Scan

Possibly as Transmissible

Officials in the UK say the B.1.617.2 variant of SARS-CoV-2 may be as transmitted as easily as the B.1.1.7 variant that was identified in the UK, New Scientist reports.

Gene Therapy for SCID 'Encouraging'

The Associated Press reports that a gene therapy appears to be effective in treating severe combined immunodeficiency syndrome.

To Watch the Variants

Scientists told US lawmakers that SARS-CoV-2 variants need to be better monitored, the New York Times reports.

Nature Papers Present Nautilus Genome, Tool to Analyze Single-Cell Data, More

In Nature this week: nautilus genome gives peek into its evolution, computational tool to analyze single-cell ATAC-seq data, and more.